Public Companies
George Tziras, CEO of Small Pharma, Sits in the Investor Hotseat on November 10th
Small Pharma ($TSXV:DMT) CEO, George Tziras, joins the Investor Hotseat to field hot questions from host, Dustin Robinson of Iter Investments. George initially…
Small Pharma ($TSXV:DMT) CEO, George Tziras, joins the Investor Hotseat to field hot questions from host, Dustin Robinson of Iter Investments.
George initially joined Small Pharma in 2015 as a director before being appointed to the role of Chief Business Officer and director of the Company in 2021. He was appointed as CEO in July 2022.
George has over 15 years of experience in investment banking and international capital markets having worked at a number of global financial institutions including Goldman Sachs, Credit Suisse, Nomura, Lehman Brothers and CIBC. His experience spans a broad range of transactions including debt and equity financings; mergers, disposals and acquisitions; private equity buyouts and debt restructurings. He has also worked across a number of industries including healthcare.
George holds a BA from the University of Oxford and a MA from the Johns Hopkins School of Advanced International Studies.
Will George be able to handle the heat in the hotseat?
As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.
If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can come back to the Hotseat livestream page at the time of the event.
To RSVP to ensure your spot, please fill out the form below.
A Transcription Will Be Available Following the Event
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Law & Regulation1 week ago
Tryp Therapeutics, Exopharm merger approved by shareholders
-
Law & Regulation1 week ago
Adastra reports record sales in 2023, but remains in the red
-
Psychedelics1 week ago
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
-
LSD1 week ago
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art